Weekly Abzena plc (LON:ABZA) Ratings on Apr 17, 2018

April 17, 2018 - By Mary Markley

Abzena plc (LON:ABZA) Corporate Logo

Abzena plc (LON:ABZA) Ratings Coverage

Total analysts of 3 have positions in Abzena Plc (LON:ABZA) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 21, 2017 according to StockzIntelligence Inc Abzena Plc has 9 analyst reports. The stock rating was maintained by FinnCap with “Buy” on Tuesday, November 21. On Monday, December 11 FinnCap maintained the shares of ABZA in report with “Buy” rating. On Tuesday, March 27 the company was maintained by Peel Hunt. On Wednesday, April 4 the firm earned “Buy” rating by Peel Hunt. On Monday, April 16 the firm earned “Buy” rating by Peel Hunt. The stock rating was maintained by Peel Hunt with “Buy” on Monday, March 5. On Tuesday, April 10 Peel Hunt maintained Abzena plc (LON:ABZA) with “Buy” rating. On Wednesday, December 13 the firm has “Buy” rating by Numis Securities given. On Monday, April 16 Numis Securities maintained Abzena plc (LON:ABZA) rating. Numis Securities has “Buy” rating and GBX 62 target. Listed here are Abzena plc (LON:ABZA) PTs and latest ratings.

16/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 New Target: GBX 42.00 Maintain
16/04/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 80.00 New Target: GBX 62.00 Maintain
10/04/2018 Broker: Peel Hunt Rating: Buy New Target: GBX 42.00 Maintain
04/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 Maintain
27/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 New Target: GBX 42.00 Maintain
05/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 New Target: GBX 42.00 Maintain
13/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain
11/12/2017 Broker: FinnCap Rating: Buy Old Target: GBX 70.00 New Target: GBX 70.00 Maintain
21/11/2017 Broker: FinnCap Rating: Buy Old Target: GBX 70.00 New Target: GBX 70.00 Maintain

ABZA reached GBX 17.35 on during the last trading session after GBX 1.1 change.Abzena plc is after having 0.00% since April 17, 2017. ABZA has 262,640 volume or 572.09% up from normal. ABZA underperformed the S&P500 by 11.55%.

Abzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally.The firm is worth 37.17 million GBP. It provides antibody drug conjugate linker, antibody humanization, and protein deimmunisation technologies and solutions, which include phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine release syndrome prior to its test in clinical trials; antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and antibody drug conjugates, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging linker.Last it reported negative earnings. The firm also provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugate and antibody drug conjugate manufacturing; and chemical synthesis comprising small molecule manufacturing, protein/BioNMR services, and analytical solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.